KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.

• DOI: 10.1200/jco.2019.37.15_suppl.9013
• Publication Date: 2020-03-12T18:25:16Z
• Authors: Shirish M. Gadgeel; Marina Chiara Gar...; Emilio Esteban; Giovanna Speranza; Enriqueta Felip; Maximilian J. Hoc...; Steven Francis Po...; Susanna Y. Cheng; Helge Bischoff; Nir Peled; Rina Hui; Martin Reck; Takayasu Kurata; Edward B. Garon; Michael J. Boyer; Jing Yang; Maria Catherine P...; Delvys Rodriguez-...
• Keywords: Pemetrexed; Carboplatin

9013 Background: Pembro + chemo significantly improved OS and PFS over alone had manageable safety as 1L therapy for metastatic nonsquamous NSCLC in the KEYNOTE-189 study (NCT02578680). The benefit was observed irrespective of PD-L1 TPS. We present updated based on longer follow-up and, first time, PFS2. Methods: Eligible pts were randomized 2:1 to pembro (n = 410) or placebo 206) pemetrexed carboplatin cisplatin 4 cycles followed by up 35 maintenance pemetrexed. Pts arm could crossover upon PD. Poststudy anticancer outcomes collected. PFS2 defined time from randomization PD per investigator after start 2L death, whichever occurred first. There no multiplicity adjustment, all P values are nominal. Data cutoff 21 Sep 2018. Results: With 18.7-mo median follow-up, continued provide (HR 0.56 [95% CI 0.45-0.70], < .00001; 22.0 mo vs 10.7 mo) 0.48 0.40-0.58], .00001). Benefit seen TPS groups (Table). 2L+ received 45% 59% (54% immunotherapy) arm. 0.49 0.40-0.59], 17.0 9.0 mo), with difference Conclusions: pemetrexed/platinum show substantial NSCLC, regardless despite 54% receiving subsequent immunotherapy. Median OS, approximately doubled chemo. These data confirm that should be given part maximize both PD-L1–expressing PD-L1–non-expressing NSCLC. Clinical trial information: NCT02578680. [Table: see text]